Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Tirzepatide (Mounjaro and Zepbound) targets both GIP and GLP-1 receptors, which may produce greater metabolic effects, but whether that translates to better outcomes for endometriosis is completely unknown
The maintenance study FIGARO UC 303 (NCT03290781) enrolled 366 responders who continued their induction dose or switched to placebo for 52 weeks, demonstrating that both 25mg and 75mg doses significantly outperformed placebo with clinical remission rates of 53.5% and 40.2% respectively versus approximately 8-13% placebo, while inclusion criteria required patients aged 1866 years with moderate to severe disease and the completed studies showed favorable safety profiles with most common adverse events being UC worsening, arthralgia, and nasopharyngitis (51)
Curve fitting and bias calculation were performed as described above in the relevant Methods section
[Crossref] 5
Who Should Consider Combining Both Medications
Open-label means that both patients and researchers knew what medication was being given, which introduces the possibility of placebo and expectation effects
US$ 28.96
US$ 25.73
US$ 25.12
US$ 25.99
US$ 22.35
US$ 20.82
US$ 24.06
US$ 25.68
US$ 28.67
